Publications
Publications
Show Results For
- All HBS Web
(172)
- Faculty Publications (95)
Page 1 of 95
Results →
- January 2025
- Case
Barilla: Feeding the Future
- October 2024 (Revised December 2024)
- Case
Kering Eyewear
By: Rohit Deshpandé, Dante Roscini and Elena Corsi
In June 2024, Roberto Vedovotto, CEO of Kering Eyewear, prepared to discuss the future of the recently acquired brands LINDBERG, a Danish optical eyewear brand, and Maui Jim, an American sunglasses brand. Vedovotto founded Kering Eyewear in 2014, convincing... View Details
- April 2024
- Teaching Note
Zegna
By: Rohit Deshpandé, Dante Roscini and James Barnett
Teaching Note for HBS Case No. 524-021. View Details
- August 2023 (Revised September 2023)
- Case
Zegna
By: Rohit Deshpandé, Dante Roscini and Elena Corsi
In 2023, the Italian luxury Zegna brand, traditionally known for formal menswear, was refocusing towards leisure wear, following a recent consumer trend. Such a move exposed the brand to more competition, in a segment where perhaps its made-in-Italy feature was less of... View Details
- January 2023
- Teaching Note
The Shuanghui-Smithfield Acquisition (A) and (B)
By: Dante Roscini
Teaching Note for HBS Case Nos. 720-042 and 720-043. View Details
- December 2022
- Teaching Note
Comviva: Exploring New Frontiers (A) and (B)
By: Dante Roscini
Teaching Note for HBS Case Nos. 721-006 and 721-010. View Details
- September 2021 (Revised October 2022)
- Supplement
Hester Pharmaceuticals (B): Securing Supply
By: Dante Roscini and John Masko
Supplements the (A) case. In late 2020, demand for Hester Pharmaceutical’s (Hester’s) breakthrough oncology drug Akrozumab was outstripping the company’s most optimistic projections. In order to increase manufacturing capacity and meet the demand, Hester was... View Details
- September 2021
- Case
Italy - 'Whatever It Takes'
By: Richard H.K. Vietor, Dante Roscini and Cecile Gambardella
- January 2021 (Revised June 2021)
- Case
Hester Pharmaceuticals (A): A Pricing Dilemma
By: Dante Roscini and John Masko
In August 2019, the leadership of Hester Pharmaceuticals (Hester) had a problem. Italy promised to be a key market for their new breakthrough oncology drug Akrozumab, but for almost two years, its single-payer healthcare system had been unable to agree with Hester on a... View Details
Keywords: Macroeconomics; Trade; Price; Global Range; Global Strategy; Globalized Markets and Industries; Health Care and Treatment; Patents; Monopoly; Negotiation; Business and Government Relations; Risk and Uncertainty; Human Needs; Business Strategy; Commercialization; Pharmaceutical Industry; Italy
- October 2020
- Technical Note
Country, Sector, Stock: A Framework for International Equity Investors
By: Dante Roscini and Vera Trojan
- September 2020 (Revised January 2021)
- Case
Comviva: Exploring New Frontiers (A)
By: Dante Roscini and Mahima Rao-Kachroo
Comviva, a mobile solutions provider active in India and 94 other countries, has had a rich history and been successful across many emerging and complex markets: Latin America, South-East Asia, Africa. What are the lessons learnt from expansion, cultural fits, and... View Details
- December 11, 2018
- Article
Free Trade Needs Nurturing—and Other Lessons from History
By: Sophus A. Reinert and Dante Roscini
- November 2018 (Revised June 2019)
- Case
The Rise of Populism and Italy's Electoral 'Tsunami'
By: Rawi Abdelal, Dante Roscini and Elena Corsi
Italy’s March 2018 elections led to a populist government that included the right-wing League and the anti-establishment 5 Star Movement. To respect their electoral promises, the two parties came up with a budget plan that provided for a public deficit at 2.4%, a... View Details
- 11 Jun 2018
- Conference Presentation
500 Days after the U.S. Election: Politics, the Economy and the Financial Markets
By: Dante Roscini